Cardiovascular Disease

Lixivaptan (Standard) is the analytical standard of Lixivaptan. This product is intended for research and analytical applications. Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.

CGS-25015 is a mercapto-containing metalloprotease inhibitor that inhibits endothelin-converting enzyme (ECE). CGS-25015 inhibits ECE activity with an IC₅₀ of 2.6 μM in porcine coronary artery smooth muscle preparations, and an IC₅₀ of 18 μM in partially purified porcine aortic endothelial cell ECE preparations. CGS-25015 inhibits endothelin production and the resulting vascular smooth muscle contractile response.

Elziverine (Ro 22-4839) is a brain circulation improvement agent with vasospasm antispasmodic effects. Elziverine is a calmodulin antagonist. Elziverine inhibits erythrocyte cell membrane rupture, platelet aggregation and lipid peroxidation.

Asundexian-d₃ (BAY-2433334-d₃) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC₅₀ of 1 nM.

Losartan-d₆ hydrochloride is deuterated labeled Losartan potassium (HY-17512A). Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC₅₀ of 20 nM.

Laprafylline (S 9795), a xanthine derivative, is a bronchodilator. Laprafylline has potent anti-bronchoconstrictive effects, inhibiting action on mast cell degranulation and phosphodiesterase (PDE) activity (IC₅₀ of 6 μM).

Choline Fenofibrate (Standard) is the analytical standard of Choline Fenofibrate. This product is intended for research and analytical applications. Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect.

Conivaptan (YM 087 free base) is an orally active dual vasopressin V_1a/V₂ receptor antagonist with K_i values of 0.48 nM and 3.04 nM for vasopressin V_1a receptor and V₂ receptor, respectively. Conivaptan competitively and reversibly blocks vasopressin-mediated antidiuresis, vasoconstriction, and cellular hypertrophy, while inhibiting CYP3A4. Conivaptan inhibits vasopressin-induced intracellular calcium, cAMP, and mitogen-activated kinase activation in vascular smooth muscle cells and cardiomyocytes. Conivaptan induces water diuresis while improving hemodynamics in heart failure models, reducing left ventricular end-diastolic pressure, vascular resistance, and organ weight. Conivaptan is used for research on hyponatremia and congestive heart failure.

DPCPX-d₄ (PD 116948-d₄) is deuterium-labeled DPCPX (HY-100937).

Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

SCH-34826 is an orally active neutral metalloendopeptidase (NEP) inhibitor that inhibits NEP and reduces the degradation of ANF, thereby enhancing its antihypertensive and diuretic effects. SCH-34826 can be used in the research of cardiovascular and renal diseases.

L-Tartaric acid (Standard) is the analytical standard of L-Tartaric acid. This product is intended for research and analytical applications. L-tartaric acid (L-(+) -tartaric acid) is an orally active weak organic acid that can be isolated from grapes. L-Tartaric acid has vasodilatory and antihypertensive effects. L-Tartaric acid can be used as flavorings and antioxidants in a range of foods and beverages. L-Tartaric acid can be used in laser frequency doubling and optical limiting applications.

MSK-195 is a potent agonist of TRPV1, with a potency of 120 nM and an efficacy of 71% in arteriolar response.

Orforglipron (Standard) is the analytical standard of Orforglipron (HY-112185). This product is intended for research and analytical applications. Orforglipron (LY3502970) (Compound 67) is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorates the type 2 diabete.

CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.

Naftopidil-d₇ (KT-611-d₇ ) is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia.

Almitrine mesylate (Standard) (Almitrine bismesylate (Standard)) is the analytical standard of Almitrine mesylate (HY-107319). This product is intended for research and analytical applications. Almitrine mesylate, a peripheral chemoreceptor agonist, inhibits selectively the Ca2+-dependent K+ channel.

Perindopril-d₃ (erbumine) is deuterated labeled Perindopril (erbumine) (HY-B0130A). Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.

Lercanidipine (hydrochloride) (Standard) is the analytical standard of Lercanidipine (hydrochloride). This product is intended for research and analytical applications. Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC₅₀ of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research.

Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC₅₀=2.1 nM) and an active metabolite of the prodrug Moexipril (HY-117281). It is formed from moexipril in vivo by side chain ester hydrolysis. Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts. It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.